Actinium Pharmaceuticals, Inc.
501 Fifth Avenue
New York City
New York
10017
United States
Tel: 646-459-4201
306 articles with Actinium Pharmaceuticals, Inc.
-
Actinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
9/26/2022
Actinium Pharmaceuticals, Inc. today announced that it will present at the Cantor Fitzgerald Oncology, Hematology & HemOnc Conference, which is being held on September 28th at the Lotte New York Palace Hotel.
-
Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones
9/21/2022
On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial expected in Q4 2022.
-
Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
9/8/2022
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will be participating in the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14, 2022.
-
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means
4/25/2022
Actinium Pharmaceuticals, Inc. today highlighted data from full patient enrollment in the pivotal Phase 3 SIERRA trial of Iomab-B.
-
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
4/19/2022
Actinium Pharmaceuticals, Inc. today highlighted its activity at the upcoming Transplantation & Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR, the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held April 23 – 26, 2022 virtually and in Salt Lake City, Utah.
-
Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa
4/12/2022
Actinium Pharmaceuticals, Inc. and Immedica Pharma AB ("Immedica") today announced entering a license and supply agreement for Iomab-B,
-
Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR
4/11/2022
Actinium Pharmaceuticals, Inc. today announced positive results from preclinical studies evaluating an anti-HER3 antibody, conjugated with an Actinium-225 (Ac-225) radioisotope payload, for targeting HER3-positive non-small cell lung cancer (NSCLC) cells.
-
Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect
4/11/2022
Actinium Pharmaceutical today announced that preclinical data highlighting the efficacy of the combination of an anti-HER3 antibody radiation conjugate (ARC) and a CD47 blocking antibody immunotherapy was presented at the American Association for Cancer Research (AACR 2021) annual meeting, which is being held April 8th – 13th.
-
Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
2/22/2022
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"),and AVEO Oncology (NASDAQ: AVEO) ("AVEO"), today announced that they have entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3.
-
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
1/5/2022
- Collaboration builds on recent data presented by Actinium at SITC demonstrating enhanced activity of targeted radiotherapies in combination with the anti-CD47 targeting antibody magrolimab in blood cancer and solid tumor models.
-
It's been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.
-
Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting
12/14/2021
Actinium Pharmaceuticals, Inc. today announced that data from the Phase 1 portion of its Actimab-A and venetoclax combination trial in patients with relapsed or refractory acute myeloid leukemia (AML) was presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH) that is being held December 11 – 14, 2021 in Atlanta, Georgia and virtually.
-
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
12/14/2021
Actinium Pharmaceuticals, Inc. today announced that updated data from the recently complete Actimab-A and CLAG-M Phase 1 combination trial being conducted at the Medical College of Wisconsin (MCW) was presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH) that is being held December 11 – 14, 2021 in Atlanta, Georgia and virtually.
-
Actinium Pharmaceuticals, Inc. Announces Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting
12/13/2021
Actinium Pharmaceuticals, Inc. today announced that positive data from the fully enrolled pivotal Phase 3 SIERRA trial of Iomab-B was presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH) that is being held December 11 – 14, 2021.
-
Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit
12/8/2021
Actinium Pharmaceuticals, Inc. announced today its participation in the Targeted Radiopharmaceuticals Summit being held virtually December 7 – 9, 2021.
-
Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference
11/12/2021
Actinium Pharmaceuticals, Inc. today announced that data highlighting an anti-HER2 antibody radiation conjugate (ARC) in combination with a CD47 blocking antibody immunotherapy in solid tumor models are being presented at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021) November 12th – 14th.
-
Actinium Highlights Actimab-A Combined with CD47 Immunotherapy Results in Upregulation of Calreticulin Leading to Enhanced Phagocytosis in AML at the Society for Immunotherapy for Cancer (SITC) Conference
11/12/2021
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that data highlighting Actimab-A in combination with a CD47 blocking antibody immunotherapy are being presented at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021) November 12th – 14th.
-
Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting
11/4/2021
Actinium Pharmaceuticals, Inc. announced multiple abstracts highlighting its Iomab-B and Actimab-A clinical programs have been accepted for presentation at the 63 American Society of Hematology Annual Meeting being held in person and virtually in Atlanta, Georgia, December 11 – 14, 2021.
-
Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy
11/4/2021
Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies for patients with unmet needs, announced that the Phase 1 trial studying Actimab-A with the salvage chemotherapy CLAG-M in patients with relapsed or refractory acute myeloid leukemia who are fit for intensive therapy has completed the planned dose escalation and patient enrollment.
-
Actinium Announces Two Abstracts Highlighting Combinations of CD47 Targeting Immunotherapy with Targeted Radiotherapies in Solid Tumors and Blood Cancers Accepted for Presentation at Society for Immunotherapy for Cancer (SITC) Conference
10/1/2021
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), today announced that two abstracts featuring targeted radiotherapies in combination with CD47 antibody immunotherapy for solid tumor and hematologic indications have been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021).